### <u>REMARKS</u>

Claims 81-83 and 87-91 presently are pending in this application. According to the outstanding Office Action, claims 81-83 and 87-91 presently stand rejected under the judicially created doctrine of obviousness-type double patenting in view of claims 1-3 of U.S. Patent No. 6,261,835; claims 11, 30 and 34 of U.S. Patent No. 6,071,695; claims 1-6, 9-18, 26-41 and 43-47 of U.S. Patent No. 5,863,758; claims 20 and 22 of U.S. Patent No. 5,712,119; claims 1-13 of U.S. Patent No. 5,670,336; claims 1-21 of U.S. Patent No. 5,652,118; claims 16-19 and 21 of U.S. Patent No. 5,614,385; and claims 18-20, 22, 24, 53-55, 57 and 59 of U.S. Patent No. 5,585,237.

Without acquiescing to the merits of the rejections, but in order to promote prosecution of the application, Applicants enclose an executed terminal disclaimer over U.S. Patent Nos. 6,261,835; 5,863,758; 5,712,119; 5,670,336; 5,652,118; 5,614,385; and 5,585,237, and a check to cover the associated fee to obviate the rejections. Applicants submit that the enclosed disclaimer and fee obviates all pending double patenting rejections except the rejection of claims 81-83 and 87-91 of the present application in view of claims 11, 30 and 34 of U.S. Patent No. 6,071,695 ("the '695 patent"), a patent originally (according to the printed patent) assigned to Creative Biomolecules, Inc., now owned by Curis, Inc., successor in interest to Creative Biomolecules, Inc.

With regard to the double-patenting rejection over claims 11, 30 and 34 of the '695 patent, Applicants respectfully submit that the rejection is improper, because claims 81-83 and 87-91 of the present application are patentably distinct from claims 11, 30 and 34 of the '695

### BEST AVAILABLE COPY

patent. Specifically, the invention of claims 11 and 30 of the '695 patent is a kit for identifying a candidate molecule capable of modulating osteogenic protein-1 (OP-1) expression in a cell comprising a receptacle containing an isolated nucleic acid comprising a reporter gene that comprises an OP-1 DNA sequence and means for detecting expression of the reporter gene. Claim 34 of the '695 patent relates to an isolated nucleic acid comprising a reporter gene in operative association with a single nucleic acid fragment of an OP-1 specific upstream non-coding sequence and further comprises part or all of an N-terminal nucleotide sequence encoding an OP-1 pro protein in operative association with the reporter gene. By contrast, the invention of independent claim 81 of the present application relates to an isolated nucleic acid molecule encoding the C-terminus of the human OP-1 protein, or a conservative amino acid variant.

It has been well established that the claimed invention as a whole is determinative of a proper double-patenting rejection. That is, the subject claim(s) must be read as a whole when analyzing a claim for double patenting, every recited claim limitation being material to the analysis. General Foods Corp. v. Studiengesellschaft Kohle mbH, 972 F.2d at 1277, 1278, 1280 (Fed. Cir. 1992). (A copy of which is enclosed for the Examiner's review as Exhibit A; relevant text is highlighted for the Examiner's convenience.) In keeping with this legal standard, Applicants submit that the kit invention defined in claim 11 or 30 of the '695 patent is clearly distinct from an isolated nucleic acid invention defined in claim 81 of the present application. Moreover, an isolated nucleic acid comprising a reporter gene in operative association with an OP-1 specific upstream non-coding sequence and an OP-1 pro protein coding sequence as defined in claim 34 of the '695 patent is clearly distinct from the isolated nucleic acid encoding the mature C-terminus of the human OP-1 protein or a conservative variant as defined in

independent claim 81 of the present application. Therefore, independent claim 81 and its dependent claims 82, 83 and 87-91 of the present application do not, in fact, claim the same inventions as claims 11, 30 and 34 of the '695 patent. Nor are they mere obvious variations of claims 11, 30 and 34 of the '695 patent.

Furthermore, as described in the MPEP, a rejection of obviousness-type double patenting is premised on the public policy of preventing the unjustified extension of a patentee's patent monopoly. Manual of Patent Examination Procedure (MPEP) § 804 II B (Magdalen Y.C. Greenlief eds., 8<sup>th</sup> ed. 2004). In this instance, the monopoly as defined by kit claims 11 and 30, or the monopoly defined by a specific nucleic acid molecule of claim 34 of the '695 patent would not, in fact, be extended upon allowance of pending claim 81 and its dependent claims, which define different, specific nucleic acid molecules or host cells. Given the facts at hand, there can be no possible extension of patent monopoly. (See also, General Foods; relevant text highlighted on page 1282.)

Accordingly, Applicants respectfully request the obviousness-type double patenting rejection over claims 11, 30 and 34 of the '695 patent be reconsidered and withdrawn.

### **CONCLUSION**

In view of the foregoing, Applicants respectfully request that the outstanding doublepatenting rejection be reconsidered and withdrawn. The Examiner is invited to contact the undersigned if the Examiner believes that a telephone conversation with Applicant's agent would be helpful in expediting prosecution of the present application.

Respectfully submitted,

Date: July 25, 2005

Reg. No. 51,551

Tel. No.: (617) 261-3198

Fax No.: (617) 261-3175

Fangti Chen

Agent for Applicant(s) Kirkpatrick & Lockhart Nicholson Graham LLP

75 State Street

Boston, Massachusetts 02109-1808

1272

the United States charged with the responsibility to act in the circumstances....

The language of section 2416(c) requires this court to examine the nature of the "facts material to the right of action." Only facts which could not reasonably be known by a relevant Government official postpone accrual. Under the facts of this case, relevant Government officials reasonably could have known of the cause of action before March 17, 1983. Thus, in the words of our sister circuits, "once the facts making up the 'very essence of the right of action' are reasonably knowable, the § 2416 bar is dropped." United States v. Gavilan Joint Community College Dist., 849 F.2d 1246, 1250 (9th Cir.1988) (quoting United States v. Kass, 740 F.2d 1493, 1497 (11th Cir.1984) (quoting S.Rep. No. 1328, 89th Cong., 2d Sess. 6 (1966), reprinted in 1966 U.S.C.C.A.N. 2502, 2508)).

Section 2416(c) does not postpone accrual of the Government's cause of action beyond March 17, 1983. On February 22, 1983, Customs inspected Commodities' warehouse. These inspecting officials found that Commodities had not marked some merchandise with proper warehouse entry numbers. The absence of the markings breached the bond. Simply viewing the boxes made this blatant breach apparent. Thus, because the Government's right of action accrued before March 17, 1983, this action is time barred.

### CONCLUSION

The Court of International Trade properly asserted jurisdiction over this action. That court also applied the proper statute of limitations. However, that court erred

4. While acknowledging that this subsection would primarily apply to cases of fraudulent concealment of Government causes of action, Congress recognized that the complexities and size of the Government could impede responsible officials' knowledge of material facts. S.Rep. No. 1328, 89th Cong., 2d Sess. 6 (1966), reprinted in 1966 U.S.C.C.A.N. 2502, 2507; see also United States v. Kass, 740 F.2d 1493, 1497 (11th Cir.1984). The legislative history of section 2416(c) explains:

in finding that the Government had filed its action within the six-year time bar.

REVERSED.



GENERAL FOODS CORPORATION, Plaintiff-Appellee,

CCHAE

STUDIENGESELLSCHAFT KOHLE mbH, Defendant-Appellant.

No. 91-1418.

United States Court of Appeals, Federal Circuit.

Aug. 11, 1992.

Rehearing Denied; Suggestion for Rehearing In Banc Declined Oct. 2, 1992.

Licensee brought suit for declaration of noninfringement, invalidity, and unenforceability as to patents relating to decaffeinated coffee. The United States District Court for the Southern District of New York, Gerard L. Goettel, J., 765 F.Supp. 121, entered judgment declaring claims of patent invalid on ground of double patenting. Patent holder appealed. The Court of Appeals, Rich, Circuit Judge, held that claims of patent describing process for decaffeination of coffee were not invalid on ground of double patenting of claims in earlier-issued patent for process of recovering caffeine for decaffeinated coffee, since the two patents did not claim the same invention, and neither claimed process was a mere obvious variation of the other.

Reversed and remanded.

It is not intended that the application of this exclusion will require the knowledge at the highest level of the Government. Responsibility in such matters may extend down into lower managerial levels within an agency. As a general proposition, the responsible official would be the official who is also responsible for the activity out of which the action arose. S.Rep. No. 1328 at 6.

BEST AVAILABLE COPY

## GENERAL FOODS v. STUDIENGESELLSCHAFT KOHLE MbH Cite as 972 F.2d 1272 (Fed. Cir. 1992)

- 00

### 1. Patents \$\sim 120\$

Claims must read as a whole in analyzing a claim of double patenting.

#### 2. Patents €=120

Claims of patent describing process for the decaffeination of coffee were not invalid on ground of double patenting; earlier issued patent describing process for recovering caffeine from decaffeinated coffee did not claim the same invention; moreover, under obvious-type double patenting analysis, neither claimed process was a mere obvious variation of the other.

### 3. Patents ≤120

Determining factor in deciding whether there is double patenting is the existence vel non of patentable difference between the two sets of claims.

### 4. Patents \$=120

Basic concept of double patenting is that the same invention cannot be patented more than once, which, if it happened, would result in second patent which would expire sometime after original patent and extend the protection timewise; double patenting also extends to merely obvious variants of what has been patented.

### 5. Patents €=120

"Obvious-type double patenting" signifies that the difference between the firstpatented invention and its variant involves only an unpatentable difference, no second patentable invention having been made.

See publication Words and Phrases for other judicial constructions and definitions.

### 6. Patents €=120

Disclosure of a patent cited in support of a double patenting rejection cannot be used as though it were prior art, even where the disclosure is found in the claims.

Paul H. Heller, Kenyon & Kenyon, New York City, argued for plaintiff-appellee. With him on the brief were Richard L. DeLucia, James Galbraith and Richard S. Gresalfi.

Arnold Sprung, Sprung, Horn, Kramer & Woods, Tarrytown, N.Y., argued for defen-

dant-appellant. With him on the brief was Nathaniel D. Kramer.

Before RICH, Circuit Judge, SKELTON, Senior Circuit Judge, and CLEVENGER, Circuit Judge.

RICH, Circuit Judge.

Studiengesellschaft Kohle mbH (SGK), as trustee for real-party-in-interest Max Planck Institute for Coal Research, appeals from the June 12, 1991 judgment of the United States District Court for the Southern District of New York, Civil Action No. 88–8343, declaring invalid claims 1 and 4 of SGK's U.S. Patent No. 4,260,639 ('639 patent), titled "Process for the Decaffeination of Coffee," on the sole ground of "double patenting," in view of SGK's earlier-issued U.S. Patent No. 3,806,619 ('619 patent), titled "Process for Recovering Caffeine." Because there is no double patenting, we reverse.

### BACKGROUND

This declaratory judgment suit is between a licensor and licensee over patents relating to decaffeinated coffee. Plaintiff, General Foods Corporation (GF), owns Maxwell House Coffee Company which manufactures decaffeinated coffee at its AMCO plant in Houston, Texas, for sale under brands such as Sanka, Maxim, Brim, Yuban, and Maxwell House. GF also owns Kaffee HAG, a processor and research company in Bremen, Germany, which is said to have been the first producer of decaffeinated coffee.

SGK developed in Europe inventions relating to decaffeination and owned five United States patents involved in this lawsuit. Learning about SGK's developments, GF entered into an exclusive license agreement with SGK effective February 1, 1978, which has now become a nonexclusive license, on which it paid royalties to SGK through 1990, since then paying further royalties under protest. The license agreement provided for advance payments totalling \$1,800,000 during the first year. Royalties were to range from 1.75% of net decaffeinated coffee sales up to 40,000,000

pounds down to 1.25% of net sales over 120,000,000 pounds.

GF brought this suit for a declaration of non-infringement, invalidity, and unenforceability as to all five patents. However, the District Court found that although all five SGK patents were licensed, SGK now asserts that only claims 1 and 4 of the '639 patent would be infringed by GF's operation at the AMCO plant and that the other four patents are no longer in suit. Although GF asserted numerous defenses against claims 1 and 4, including invalidity for "obviousness-type double patenting," non-infringement, obviousness under 35 U.S.C. § 103, non-enablement under 35 U.S.C. § 112, and unenforceability due to inequitable conduct before the Patent and Trademark Office (PTO), the District Court issued an Order of Trial on April 5, 1991, on GF's motion, to "bifurcate the issue of double patenting." The order further stated, "If the decision does not dispose of the action, trial will then immediately continue on the remaining issues."

The District Court held a separate trial on the single issue of double patenting. A judgment was entered holding claims 1 and 4 of the '639 patent invalid, thus terminating GF's declaratory judgment suit seeking invalidity of the only patent it was alleged to be infringing and putting an end to its obligation to pay SGK royalties under its contract. 765 F.Supp. 121.

This appeal followed and, as above stated, there is only one issue for us to decide—is there double patenting. We shall first discuss the facts regarding the two patents involved and then the law of double patenting as it applies to those facts.

### Patent Claims

Preliminarily, in order to better focus on the crucial aspects of the patents under discussion, we make the following elementary observations about patent claims. The patent document which grants the patentee a right to exclude others and hence bestows on the owner the power to license, consists of two primary parts: (1) a written description of the invention, which may and here does include drawings, called the

"specification," enabling those skilled in the art to practice the invention, and (2) claims which define or delimit the scope of the legal protection which the government grant gives the patent owner, the patent "monopoly." As stated by Judge Lane, who served on both of our predecessor courts, in In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA1970), "A claim is a group of words defining only the boundary of the patent monopoly." (Emphasis ours.) The Supreme Court has likened patent claims to the description of real property in a deed "which sets the bounds to the grant which it contains. It is to the claims of every patent, therefore, that we must turn when we are seeking to determine what the invention is, the exclusive use of which is given to the inventor by the grant provided for in the statute,—'He can claim nothing beyond them." Motion Picture Patents Co. v. Universal Film Mfg. Co., 243 U.S. 502, 510, 37 S.Ct. 416, 418, 61 L.Ed. 871 (1917) (emphasis ours).

That being the essential nature of patent claims, it follows that each claim is an entity which must be considered as a whole. It cannot be said-though it often is, incorrectly, by the uninitiated-that a part of a claim is "claimed" subject matter. For example, a claim to a process comprising the step A followed by step B followed by step C defines, as a matter of law, only the A-B-C process and one cannot properly speak of any single step as being "claimed", for it is not; all that is claimed is the process consisting of the combination of all three steps. Such a claim, therefore, creates no patent right or monopoly in step A, no right to prevent others from using step A apart from the combination of steps A-B-C. Step A is not "patented."

Another way of stating the legal truism is that patent claims, being definitions which must be read as a whole, do not "claim" or cover or protect all that their words may disclose. Even though the claim to the A-B-C combination of steps contains a detailed description of step A, that does not give the patentee any patent

right in step A and it is legally incorrect to say that step A is "patented."

These legal rules about construing claims are repeated here because the law of double patenting is concerned *only* with what patents *claim*. "Double patenting," therefore, involves an inquiry into what, if anything, has been claimed twice.

# The Patent in Suit and its Claimed Invention

Coffee beans contain a small percentage of caffeine which must be removed to produce decaffeinated coffee. The inventor, Kurt Zosel, working in Germany for SGK, discovered that moist (i.e., containing water) "supercritical" carbon dioxide, that is, carbon dioxide above its critical temperature and critical pressure, was an excellent solvent for taking the caffeine out of coffee beans. That was the basic invention. The parties and the trial court have referred to the patent on this invention as "the decaffeination patent."

A U.S. application for patent on this invention was filed January 28, 1971, serial No. 110,428. This application was prosecuted to the point where all pending claims were allowed following the usual debate with the examiner over unobviousness in view of prior art references. The official Notice of Allowance was mailed by the PTO March 8, 1973. Payment of the base issue fee was due within three months, June 8, 1973.

Upon examining the 13 allowed claims prior to issue, Zosel and/or his attorneys realized that all claims were limited to raw coffee beans and it was concluded that the application disclosure would support broader claims not limited to raw coffee, but broad enough to include roasted coffee; i.e., claims simply calling for "coffee." It was decided, therefore, to file a continuation-in-part application (a CIP) with such broader claims. This was done within the time limit allowed by PTO rules and application Serial No. 364,190 was filed on May 25, 1973. Original application Serial No. 110,428, according to the usual practice. was allowed to go abandoned.

The try for broader claims did not succeed in a prosecution that was hard fought and went all the way to the PTO Board of Patent Appeals and Interferences (Board). Zosel and his assignee SGK ended up with a Board decision on July 12, 1979, that allowed claims to no more than had originally been allowed, claims to the new process as applied to raw coffee beans. The Board held the disclosure in Zosel's original application did not support claims naming "coffee" generally, wherefore he was entitled only to the filing date of the CIP, to which he had added supporting disclosure. Given that filing date, there was new prior art which barred claims not restricted to raw coffee. The Board said:

We affirm the rejection of claims 1-14 [the new broad coffee claims] under 35 USC 102(d) as anticipated by the British patent. Contrary to appellant's assertion, the decaffeination of coffee in general, i.e. from both its raw and roasted state, by the claimed expedient is not implicit in the disclosure of the parent application.

We are not concerned on this appeal with this aspect of the Board's decision. It simply concluded Zosel's effort to get broad "coffee" claims.

The more interesting aspect of the Board's decision relates to the double patenting issue now before us. During the CIP prosecution, the Examiner had made obviousness-type double patenting rejections based on the claims of Zosel's U.S. Patent No. 3,806,619, issued April 23, 1974, the same '619 patent relied on by the District Court in support of the double patenting decision here under review. The double patenting issue was extensively debated between the Examiner and applicant's attorney and went to the Board on appeal from the Examiner's final rejection. The Board reversed the Examiner's rejections for obviousness-type double patenting. The Board concluded (emphasis ours):

In re Borah, 53 CCPA 800, 354 F.2d 1009, 148 USPQ 213 [ (1966) ], supports appellant's position that the test for double patenting is whether or not the subject matter of the patent claims is obvious from the subject matter of the claims

at issue. Clearly, here, steps (b) through (j) of the ['619] patent claims are not suggested by nor obvious from the claims at bar, the patent claims being a separate and distinct improvement invention thereover, and, consequently, no double patenting rejection is seen to be proper.

Thereafter, Zosel cancelled the rejected claims, received a Notice of Allowance, and the '639 patent in suit was issued on April 7, 1981.

Claims 1 and 4 of the '639 patent, held invalid in this suit for double patenting in view of the '619 patent, contrary to the unanimous decision of the Board on the identical issue, read as follows:

- 1. A process for the decaffeination of raw coffee which comprises contacting the raw coffee with water-moist carbon dioxide above its critical temperature and critical pressure to effect removal of caffeine therefrom and recovering a substantially decaffeinated coffee, the amount of water in the carbon dioxide being sufficient to effectuate said removal of the caffeine from the coffee.
- 4. A process as claimed in claim 1, in which the contact with the moist carbon dioxide is effected for a period of from 5 to 30 hours.

It will be observed that this process consists of two steps: (1) a caffeine removal step and (2) a decaffeinated-coffee recovery step. The claim 4 time limitation addition to claim 1 is of no significance to the decision of the issue here.

# The Invention of Claim 1 of the '619 Patent Relied on Below to Show Double Patenting

Zosel, more than a year after he had filed his foreign application to patent his decaffeination process, on which his U.S. parent and CIP applications were based, made a further invention which the parties have characterized as an "improvement" on the original process. It is, however, a separate invention, unrelated to the decaffeination

1. Two spellings of "caffeine" appear in this opinion because the '619 patent omits the terminal

invention defined in claims 1 and 4. Its purpose was to effect an efficient removal from the supercritical carbon dioxide solvent, used to extract caffeine from the raw coffee beans, of the caffeine removed so as to obtain caffeine of better than 95% purity. The shorter version of the general description of this recovery process in the '619 patent is as follows: 1

[The process for recovering caffeine] which comprises removing the caffeine from the caffein-loaded carbon dioxide by repeated treatment with water and recovering the caffein and the water from the resultant dilute aqueous caffein solution by recycling a stream of air or nitrogen under a superatmospheric pressure of about 1 to 5 atmospheres through the heated caffein solution and a heat exchanger, separating the caffein and the condensed water and recycling after admixture of cold caffein solution the gas through the heat exchanger in countercurrent flow relation and meeting the heat requirement by supplying heat to the hot caffein solution.

The patent specification then proceeds with a detailed description of the recovery process in conjunction with a drawing of the processing apparatus employed.

What has caused much of the argument and most of the confusion in this case is the brief reference in the '619 patent to the '639 patent decaffeination process as the source of the caffeine in the "caffeinloaded carbon dioxide" which is the input to the recovery process. The totality of that reference in the '619 patent is in the opening paragraphs of the specification:

Austrian Pat. No. 290,962 and U.S. [CIP] application Ser. No. 364,190, filed May 25, 1973 disclose a process for decaffeinating green coffee, wherein moist carbon dioxide is recycled through a bed of green coffee and a bed of activated charcoal. The moist carbon dioxide passes through the green coffee bed in supercritical state and through the bed of activated charcoal at a lower temperature in

"e" except in its title.

liquified state. The moist carbon dioxide in supercritical state is loaded thereby with the caffein of the green coffee and the caffein is absorbed on the activated charcoal.

The recovery of the caffein from the activated charcoal is not described in the patent mentioned above.

The parties and the trial court have appropriately referred to the '619 patent as "the caffeine recovery patent."

It should be amply clear by now that the decaffeination invention and the caffeine recovery invention are separate and distinct inventions, directed to different objectives, and patentably distinguishable one from the other. Neither is statutory "prior art" to the other because the patent applications were copending and, further, because there can be no "prior invention by another" (cf. 35 U.S.C. § 102(g)) because both are the inventions of Zosel.

Claim 1 of the '619 patent, on the basis of which the District Court found double patenting, reads:

- 1. A process for obtaining caffein from green coffee which comprises:
  - a. contacting moist carbon dioxide in supercritical state with the coffee in a caffein absorption zone for absorption of caffein by the moist carbon dioxide, b. withdrawing the moist carbon dioxide containing absorbed caffein from the absorption zone and contacting it with water for extraction of caffein from the moist carbon dioxide in an extraction zone for formation of an aqueous solution of caffein,
  - c. recirculating the moist carbon dioxide between the absorption zone and the contacting zone,
  - d. withdrawing aqueous solution of carbon dioxide from the extracting zone and introducing it into an evaporating zone, passing a stream of air or nitrogen through the aqueous solution in the evaporating zone for evaporation of water from the solution and concentration of caffein in the aqueous solution, and withdrawing a concentrated aqueous solution from the evaporating zone,

- e. withdrawing the air or nitrogen laden with water vapor from the evaporating zone and cooling it for condensation of water and separating the water from the air or nitrogen in a separating zone,
- f. recirculating the air or nitrogen between the evaporating zone and the separating zone,
- g. admixing aqueous solution of carbon dioxide from the extraction zone with the air or nitrogen conveyed from the separating zone to the evaporating zone.
- h. passing the air or nitrogen laden with water vapor and the admixture formed in step (g) in indirect heat exchange relation between the evaporating zone and the separating zone, for cooling of the air or nitrogen laden with water vapor for the condensation of step (e) and heating said admixture for heating the aqueous solution for the evaporation, and

[sic-no step i.]

j. supplying additional heat to the aqueous solution for the evaporation.

That this claim 1 of the '619 patent is the sole basis of the ultimate double patenting holding of the trial court is shown in its Conclusion of Law 24, which reads:

24. For all the foregoing reasons, we find [sic, hold] that claim 1 of the decaffeination patent ['639] is obvious from claim 1(a) of the caffeine recovery patent ['619]. Consequently, plaintiff is entitled to a judgment declaring claim 1 of the decaffeination patent invalid on the ground of obviousness-type double patenting.

### ANALYSIS

[1,2] Double patenting is altogether a matter of what is claimed. Claim interpretation is a question of law which we review de novo. Loctite Corp. v. Ultraseal Ltd., 781 F.2d 861, 228 USPQ 90 (Fed.Cir.1985). As we construe the claims here involved, claims 1 and 4 of the patent in suit, '639, define a process of decaffeinating raw coffee with supercritical water-moist carbon

dioxide and recovering the decaffeinated coffee. They say nothing about what happens to the caffeine. Claim 1 of the '619 patent, relied on to show double patenting, defines a 9-step process of "obtaining caffein from green coffee." Anything less than a process with all 9 steps is not what is claimed, and is, therefore, not patented. Claims must be read as a whole in analyzing a claim of double patenting. Carman Indus., Inc. v. Wahl, 724 F.2d 932, 940, 220 USPQ 481, 487 (Fed.Cir.1983) ("we wish to clarify that double patenting is determined by analysis of the claims as a whole.") These two inventions, decaffeination of coffee and recovery of caffeine, are separate, patentably distinct inventions between which there cannot be double patenting. Clearly the two patents do not claim the same invention, and this is not argued. Under an obviousness-type double patenting analysis, neither claimed process is a mere obvious variation of the other. No other kind of "double patenting" is recognized, so there is no double patenting. That concludes the case so far as this appeal is concerned. A discussion of the law which supports our conclusion follows.

### No Double Patenting Between Patentably Distinct Inventions

The opinion in In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA1970), undertook a "restatement of the law of double patenting as enunciated by this court." To summarize it, the opinion says that the first question is: Is the same invention being claimed twice? If the answer to that is no, a second question must be asked: Does any claim in the application define merely an obvious variation of an invention claimed in the patent asserted as supporting double patenting? If the answer to that question is no, there is no double patenting. The court was speaking, of course, about the PTO rejection of a pending patent application intended to forestall double patenting. If the rejected claim defines more than an obvious variation, it is patentably distinct.

One of our most recent double patenting decisions is *In re Braat*, 937 F.2d 589, 19

USPQ2d 1289 (Fed.Cir.1991) in which we held:

do

pa

cla

op

ab "ч

ob Tł

m

de

es

In

(C

tc

Thus, a double patenting rejection is sustainable here only if claims 5/1 and 6/1 of Dil are not patentably distinct from the subject matter defined by the rejected claims of Braat.... [The claim numbers refer to dependent claims 5 and 6, both depending from claim 1.]

... [W]e conclude that the claims of the Braat application and the Dil patent are patentally distinct, and that the double patenting rejection was in er-

Id. at 594, 19 USPQ2d at 1293 (emphasis added). With respect to extension of patent protection we said in *Braat*:

It is true that allowance of the Braat application will result in some timewise extension of Philips' patent protection of the Dil structure. This is because Braat's claims dominate the invention of Dil claims 5/1 and 6/1. As our predecessor court pointed out in Borah, in analogizing the Stanley decision, "We see ... that as a matter of law the extension of protection objection is not necessarily controlling."

Id. (emphasis added). Just a fortnight before Braat we decided Symbol Technologies, Inc. v. Opticon, Inc., 935 F.2d 1569, 19 USPQ2d 1241 (Fed.Cir.1991), in which the court said:

Furthermore, even if there had been a breach of the restriction requirement, we would reject Opticon's argument on the *ultimate* obviousness-type double patenting *inquiry:* whether the claims of the '186 patent are *patentably distinct* from the claims of the '297 patent. See In re Borah, 354 F.2d 1009, 1017, 148 USPQ 213, 220 (CCPA1966) (crux of obviousness-type double patenting inquiry lies in comparison of claims)....

Id. at 1580, 19 USPQ2d at 1249 (emphasis added).

[3] The extensive opinion in *In re Bo-rah*, 354 F.2d 1009, 148 USPQ 213 (CCPA1966), in its concluding pages, shows beyond question that the determining factor in deciding whether or not there is

double patenting is the existence vel non of patentable difference between two sets of claims. The phrases actually used in the opinion include "patentably distinguishable," "patentable distinctions," and "whether such differences would have been obvious to one of ordinary skill in the art." They are all equivalent. The opinion summarizes two earlier cases, spanning three decades, to the same effect, citing them as established law with full approval, namely, In re Stanley, 214 F.2d 151, 102 USPQ 234 (CCPA1954), and In re Calvert, 97 F.2d 638, 38 USPQ 184 (CCPA1938).

Before leaving *Borah*, we call attention to the following statement there made in the court's discussion of *Stanley*:

In Stanley, this court sanctioned, in 1954, the issuance of a dominating patent to the owner of the improvement patent which had issued in 1950, notwithstanding the owner's protection would thereby be extended beyond the expiration of the improvement patent by several years. We see, therefore, that as a matter of law the extension of protection objection is not necessarily controlling.

354 F.2d at 1017, 148 USPQ at 220.

We find in the facts of the instant case a parallel situation. The facts here indicate that in the commercial decaffeination of raw coffee the processor is interested, for economic reasons, not only in the effective decaffeination of raw coffee but in the effective recovery of pure caffeine as a byproduct. Therefore, both of Zosel's inventions are preferably used in the same commercial process. These patentably distinct process inventions are covered by separate patents, however, which happen to expire at different times. Each process, nevertheless, is capable of being used by itself. The fact that it may be desirable to use both inventions in the same commercial process does not result, however, in any recognized form of double patenting, or in the "extension" of either patent; each patent has a term of seventeen years.

A licensee which has taken a license under both patents, choosing to use the inventions claimed in both patents in the same commercial process, must know that, in the

absence of some agreement to the contrary, it is not excused from paying royalty after one of the patents expires while the other is still in force and the invention it claims is being used. In the 1978 exclusive license agreement entered into by GF and SGK, the licensed "Patent Rights" were set forth in a schedule of some 21 U.S. and foreign patents and applications with a wide range of expiration dates. Included therein are patent '619 which had issued in 1974 and both the parent and CIP applications, Serial Nos. 110,428 and 364,190 which resulted in the '639 patent in suit in 1981. The record shows that before the license was entered into, GF had been supplied with copies of the parent and CIP application prosecution histories and was therefore fully informed about aspects of the '639 prosecution history it now attempts to use to show invalidity on double patenting grounds, particularly the decision to file the CIP application which GF now depicts as a deliberate effort by SGK to "extend" its protection by obtaining "a 24year patent," to cover the inventions of others, etc. It has to be considered a bit odd that after enjoying the benefits of a license to use the principal invention which caused it to take a license in 1978-the decaffeination process which it knew was not yet patented, not the caffeine recovery "improvement" which it no longer wishes to use-and although fully informed about the prosecution of the patent on that decaffeination invention, it comes up with the contention a decade later that that patent is invalid and files the present declaratory judgment suit in 1988 to test its theory. At least, it would seem odd but for the realization that if its theory can be put across, it will save GF a lot of money. During the time GF was an exclusive licensee, its interest in having the broadest and longest patent protection on the decaffeination process was as great as SGK's.

Determining What Is Patented By Correct Claim Interpretation Is Essential To Determination Of Obviousness-Type Double Patenting Issues

[4] The basic concept of double patenting is that the same invention cannot be

patented more than once, which, if it happened, would result in a second patent which would expire some time after the original patent and extend the protection timewise. But double patenting law has always been more inclusive. Double patenting law principles extend to merely obvious variants of what has been patented. Step one of the analysis is to determine what that is. Claims are the determinants.

[5] In the cases, which are mostly from the Court of Customs and Patent Appeals, now merged with the former Court of Claims to form this court, the development of the law came to a turning point in In re Zickendraht, 319 F.2d 225, 138 USPQ 22 (CCPA1963), particularly in the concurring opinion therein. Soon thereafter the obvious variant kind of double patenting came to be known as "obviousness-type" double patenting, which signifies that the difference between the first-patented invention and its variant involves only an unpatentable difference, no second patentable invention having been made. The Zickendraht concurring opinion suggested that an obviousness-type double patenting situation could be overcome by filing a terminal disclaimer, which had been provided for in section 253 of the 1952 patent act for that very purpose. However, where the two inventions are patentably distinct, no disclaimer is called for. Where there is a second patentable invention, as there is here, because the difference is not an obvious one, it is important to bear in mind that comparison can be made only with what invention is claimed in the earlier patent, paying careful attention to the rules of claim interpretation to determine what invention a claim defines and not looking to the claim for anything that happens to be mentioned in it as though it were a prior art reference. This was not done by the trial court. Rather, it was carefully misguided by GF's arguments into doing exactly the opposite, as we shall now show.

It should suffice, we feel, to point out the principal error into which the trial court was led which resides in a complete misinterpretation of claim 1, set forth above, of the '619 patent on the caffeine recovery

process, now expired. We have quoted above, immediately following claim 1 of the '619 patent, Conclusion of Law 24 which is the ultimate error. The gist of it is that claim 1 of patent '639 in 'suit is "obvious from claim 1(a)" of patent '619. Of course, there is no such thing as "claim 1(a)," a term used no less than 11 times throughout the Findings of Fact and Conclusions of Law. There is a claim 1 and the first step of its 9 recited steps is designated "(a)." And that step recites the essence of the very same process claimed in the '639 patent in suit but, in accordance with the principles of claim construction discussed early in this opinion, step (a) is not "claimed" in the '619 patent, nor is it "patented" or "covered" as the trial court seems to have thought it was as shown by its Finding of Fact 58 which says: "It was obvious to one of ordinary skill in the art that supercritical carbon dioxide would substantially decaffeinate coffee, as otherwise it would not be claimed in claim 1 of the '619 patent...." (Emphasis ours.) This concept violates the fundamental rule of claim construction, that what is claimed is what is defined by the claim taken as a whole, every claim limitation (here each step) being material. What is patented by claim 1 of '619 is a 9-step caffeine recovery process, nothing more and nothing less.

A further error of the trial court in dealing with the '619 patent's claim 1 was in looking, not at what invention it defines, but at whatever the claim discloses, illustrated by Findings of Fact 68 and 69.

- 68. There cannot be double patenting here unless the plaintiff [GF] establishes, inter alia, that claims 1 and 4 of the '639 patent are obvious from the claims of the '619 patent, as interpreted by the specification in view of the prior art. This is perfectly sound law if one construes "from the claims" to mean from the invention defined by the claims, but in the next finding the court jumps the track (emphasis ours):
  - 69. Claim 1(a) of the '619 patent anticipates, or at least renders obvious, the inventions of claims 1 and 4 of the '639 patent because every step of

claims 1 and 4 of the '639 patent is set forth in claim 1(a) of the '619 patent....

This clearly is using nothing but the disclosure of clause (a) of claim 1 as though it were prior art, and in not reading claim 1 to determine what invention it defines—like the metes and bounds of a deed. We repeat, clause (a) of claim 1 is not a claim, patent '619 does not claim clause (a) but a 9-step process of which (a) is the first step, and double patenting is based entirely on what is claimed, reading each claim as an entirety to determine what invention it defines.

A further illustration of the same misconstruction of claims by reading them for what they disclose rather than to determine what they define appears in Conclusion of Law 18 which says, in part, "in this case the only relevant inquiry is whether the claims of the first patent 'disclose [] to one of ordinary skill in the art' the claims of the second patent." (Emphasis ours.) The source of the quoted phrase is not given. The court failed to observe the distinction between a claim as a written disclosure and a claim as a definition of an invention.

How the meaningless, confusing, and highly misleading expression "claim 1(a)" got injected into this case "is a puzzlement." We are also perplexed as to what the trial court meant by it in its constantly reiterated use. There is some evidence the court was led to believe that clause (a) of claim 1 was actually a claim in the sense that the words "claim" and "claimed" are used in the law of double patenting and in patent law generally. If that is so, we express sincere sympathy for the trial judge in his efforts to understand this double patenting issue, a subject usually fraught with difficulty. There is a much stronger indication that GF's counsel are responsible for the use of the term "claim 1(a)." Whether they originated it or not, they have perpetuated it in the course of ten pages of their brief before this court (Main Brief at pages 39-49, the term appearing at least once on every page except page 47 and altogether 17 times). This fictitious "claim 1(a)," which is supposed to

define some already patented invention, is then argued to make the invention claimed in the patent in suit obvious, if not anticipated which is the epitome of obviousness. This may seem plausible because "claim 1(a)" is a description of that very invention. But, in the first place, this argument fails because it totally ignores the rules of claim interpretation and, in the second place, it is used as though it is a prior art disclosure for everything recited in claim 1 being applied to support an obviousness rejection under 35 USC 103. This is impermissible in the law of double patenting.

### Precedents Prohibit Use of Disclosure of Patent Cited to Support Double Patenting

[6] Our precedent makes clear that the disclosure of a patent cited in support of a double patenting rejection cannot be used as though it were prior art, even where the disclosure is found in the claims. See, e.g., Braat, 937 F.2d at 594 n. 5, 19 USPQ2d at 1293 n. 5 ("The patent disclosure must not be used as prior art"); Vogel, 422 F.2d at 442, 164 USPQ at 622 (in considering obviousness-type double patenting, "the patent disclosure may not be used as prior art"); In re Plank, 399 F.2d 241, 242, 158 USPQ 328, 329 (CCPA1968) ("Its claims [Plank et al. patent] are used as the basis for a double patenting rejection. It is not a prior art reference"); In re Aldrich, 398 F.2d 855, 859, 158 USPQ 311, 314 (CCPA1968) ("double patenting rejections cannot be based on section 103, ... or on the disclosures of the patents whose claims are relied on to demonstrate double patenting or on the 'disclosures' of their claims.... [P]atent claims are looked to only to see what has been patented, the subject matter which has been protected, not for something one may find to be disclosed by reading them"); In re Boylan, 392 F.2d 1017, 1018 n. 1, 157 USPQ 370, 371 n. 1 (CCPA1968) ("in analyzing cases of these types, it must always be carefully observed that the appellant's patent is not 'prior art' under either section 102 or section 103 of the 1952 Patent Act"); In re Braithwaite, 379 F.2d 594, 600 n. 4.

154 USPQ 29, 34 n. 4 (CCPA1967) ("While analogous to the non-obviousness requirement of 35 U.S.C. § 103, that section is not itself involved in double patenting rejections because the patent principally underlying the rejection is not prior art"); Borah, 354 F.2d at 1018, 148 USPQ at 221 ("We have no prior art here"); In re Sutherland, 347 F.2d 1009, 1015, 146 USPQ 485, 491 (CCPA1965) ("Nor is obviousness invariably involved in 'double patenting' rejections. Claims relied on in such [double patenting] rejections often disclose or name the very thing being claimed [in the rejected claims]. Furthermore, the words of such claims cannot be treated as 'prior art,' ... but are looked to solely for the purpose of determining what has already been patented. They are not treated as prior art for the simple reason they are no more 'prior art' under the statue than the specification") (citation omitted); In re Sarett, 327 F.2d 1005, 1013, 140 USPQ 474, 481 (CCPA1964) ("We are not here concerned with what one skilled in the art would be aware [of] from reading the claims but with what inventions the claims define.")

# The '619 Patent During Its Term Provided No Protection for the Invention Claimed in the '639 Patent

Double patenting is intended to prevent unjustified extension of protection. Because the trial court misunderstood the construction of patent claims, it failed to appreciate that the invention of the second-to-issue '639 patent received no protection from the first-issued '619 patent because no claim of the latter covers the decaffeination process. Protection of that invention did not begin until the '639 patent issued on April 7, 1981. It will expire 17 years thereafter. There is no 24-year patent protection as GF alleges.

All that is claimed in the '619 patent is the caffeine recovery invention. To clearly understand this one must look at all the claims of '619. There are only 6 claims and the broadest is independent claim 4 which we quote as showing the maximum patent coverage of this patent:

- 4. A process for concentrating a dilute aqueous solution of caffein, which comprises:
  - a. introducing the dilute aqueous solution into an evaporating zone, passing a stream of air or nitrogen through the aqueous solution in the evaporating zone for evaporating of water from the aqueous solution and concentration of caffein in the aqueous solution, and withdrawing a concentrated aqueous solution from the evaporating zone,
  - b. withdrawing the air or nitrogen laden with water vapor from the evaporating zone and cooling it for condensation of water and separating the water from the gas in a separating zone,
  - c. circulating the air or nitrogen between the evaporating zone and the separating zone,
  - d. admixing the dilute aqueous solution of caffein and the air or nitrogen conveyed from the separating zone to the evaporating zone,
  - e. passing the air or nitrogen laden with water vapor and the admixture formed in step (d) in indirect heat exchange relation between the evaporating zone and the separating zone, for cooling of the air or nitrogen laden with water vapor for the condensation of step (b) and for heating said mixture for heating the aqueous solution for evaporation of step (a), and
  - f. supplying additional heat to the aqueous solution for the evaporation.

Comparison of this claim 4 with claim 1 will show the general correspondence of claim 4 to steps (d)-(j) of claim 1 which further references carbon dioxide in steps (d) and (g) and shows in steps (a)-(c) the source of the caffeine to be coffee which has been treated with moist supercritical carbon dioxide, making claim 1 more limited but still containing all the limitations of claim 4.

Since a patent is not infringed unless one or more claims are infringed and none of the '619 claims are infringed by one practicing the decaffeination process claimed in patent '639 without more, the '619 patent did not cover the '639 process and a patent thereon cannot extend the protection granted by the now expired '619 patent.

As the '619 patent states in its second paragraph, previously quoted herein, the recovery of the caffeine produced by the '639 patent is not described in that patent, which was then only the CIP application, Ser. No. 364,190. Furthermore, by these statements in the '619 patent the public was put on notice of the existence of the CIP application's pendency, of the invention therein described, and the probability of a future patent.

### Other Arguments

Both parties' briefs have made and debated, and we have considered, numerous arguments other than those we have discussed, the majority of which we find irrelevant and all of which we find it unnecessary to comment on.

### CONCLUSION

Finding the judgment of the District Court that claims 1 and 4 of the '639 patent are invalid for obviousness-type double patenting in view of claim 1 of the '619 patent to have been in error, essentially because of the distressing failure to adhere to firmly established and universally understood rules of claim interpretation, that judgment is reversed and the case is remanded for further proceedings.

#### COSTS

- (a) Appellant requests us to vacate the award of costs on the double patenting trial. We deny the request and leave it to the trial court to review and decide in view of the outcome.
  - (b) Costs on this appeal to appellant. REVERSED AND REMANDED.



### Richard M. FRANCHI, Plaintiff-Appellant,

Harry F. MANBECK, Jr., Assistant Secretary of Commerce & Commissioner of Patents & Trademarks, Defendant-Appellee.

No. 92-1085.

United States Court of Appeals, Federal Circuit.

Aug. 12, 1992.

Person seeking registration to practice before United States Patent and Trademark Office (USPTO) brought suit against Commissioner of Patents and Trademarks to compel Commissioner to allow plaintiff to practice before USPTO and for money damages. The United States District Court for the District of Connecticut, Peter C. Dorsey, J., dismissed for lack of subject matter jurisdiction. Plaintiff appealed. The Court of Appeals, 947 F.2d 631, concluded that it lacked appellate jurisdiction and transferred appeal. The Court of Appeals, Rich, Circuit Judge, held that: (1) District Court for the District of Columbia was the exclusive forum for plaintiff to obtain review of refusal to register to practice before USPTO; (2) decision not to exercise jurisdiction under mandamus statute for federal officers was not abuse of discretion; and (3) sovereign immunity prevented claim for money damages.

Affirmed.

### 1. Patents = 113(1)

United States District Court of the District of Columbia was exclusive forum for applicant to obtain review of decision by Commissioner of Patent and Trademark, refusing to register applicant to practice before Patent and Trademark Office, even though complaint was styled as action for mandamus. 28 U.S.C.A. § 1338(a); 35 U.S.C.A. § 32.

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
□ other:

### IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.